Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06025214 |
Recruitment Status :
Recruiting
First Posted : September 6, 2023
Last Update Posted : September 6, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bioequivalence | Drug: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals Drug: ADVAIR DISKUS® 500/50 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 34 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study |
Masking: | Single (Outcomes Assessor) |
Masking Description: | laboratory-blinded |
Primary Purpose: | Other |
Official Title: | A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers |
Actual Study Start Date : | August 22, 2023 |
Estimated Primary Completion Date : | September 22, 2023 |
Estimated Study Completion Date : | October 31, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Test
Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
|
Drug: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
2 inhalations in one study period
Other Name: Test |
Active Comparator: Reference
ADVAIR DISKUS® 500/50
|
Drug: ADVAIR DISKUS® 500/50
2 inhalations in one study period
Other Name: Reference |
- Cmax for Fluticasone Propionate (FP) [ Time Frame: up to 36 hours post-administration ]Maximum plasma concentration, it is read directly from the raw data
- Cmax for Salmeterol (SAL) [ Time Frame: up to 36 hours post-administration ]Maximum plasma concentration, it is read directly from the raw data
- (AUC0-t) for Fluticasone Propionate (FP) [ Time Frame: up to 36 hours post-administration ]Area under the plasma concentration curve from time 0 to the last measured
- (AUC0-t) for Salmeterol (SAL) [ Time Frame: up to 36 hours post-administration ]Area under the plasma concentration curve from time 0 to the last measured
- AUC0-∞ [ Time Frame: up to 36 hours post-administration ]Area under the plasma concentration-time curve extrapolated to infinity
- Tmax [ Time Frame: up to 36 hours post-administration ]Time until Cmax is reached, it is read directly from the observed concentrations
- t1/2 [ Time Frame: up to 36 hours post-administration ]Plasma concentration halflife, it is calculated from the ratio 0.693/λZ
- λz [ Time Frame: up to 36 hours post-administration ]Terminal elimination rate constant, calculated from the slope of the final phase of the ln-concentration curve versus time with regression analysis
- Residual Area [ Time Frame: up to 36 hours post-administration ][AUC(0-∞)-AUC(0-t)]/AUC(0-∞)]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy volunteers of both genders, aged ≥18 and ≤60 years.
- Subjects with Body Mass Index (ΒΜΙ) ≥18.5 and <30.0 kg/m2.
- Healthy volunteers are declared healthy based on medical history, physical examination, ECG, pulmonary function test (a forced expiratory volume in 1 second (FEV1) ≥80% of the predicted normal value), and clinical laboratory values within the laboratory stated normal range; if not within this range, they must be without any clinical significance according to the Investigator.
-
Females who participate in the study are either unable to gestate [i.e. post-menopausal (absence of menses for 12 months prior to drug administration), hysterectomy, bilateral oophorectomy, tubal ligation at least 6 months prior to drug administration] or at reproductive age; Females of reproductive age if sexually active, must be practicing an effective method of birth control within 14 days prior to the first drug administration and throughout the study.
Reliable contraception methods are considered the following:
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal or transdermal progestogen-only hormonal contraception associated with inhibition of ovulation oral, implantable or injectable intrauterine device (IUD) intrauterine hormone-releasing system (IUS) bilateral tubal occlusion vasectomised partner sexual abstinence
- Subjects that are non-smokers
- Subjects that, in the opinion of the principal investigator/medical officer, are able to communicate and comply with the study procedures and protocol restrictions as evidenced by the Informed Consent Form (ICF) duly read, signed and dated by the subject prior to study initiation.
- Subjects able to use the inhalers according to given instructions, as judged by the Investigator or study nurse
Exclusion Criteria:
- Hypersensitivity to the active substance(s) or to the excipient (lactose which contains small amounts of milk protein may cause allergic reactions) or related class (any sympathomimetic drug or any inhaled, intranasal, or systemic corticosteroid therapy) of the medicinal product
- Clinically significant illness or surgery within four weeks prior to dosing.
- Clinically significant ECG abnormalities or vital sign abnormalities (seated systolic blood pressure <90 or >140 mmHg, seated diastolic blood pressure <50 or >90 mmHg or heart rate less than 50 or over 100 bpm) at screening.
- Clinically significant history or presence of chronic bronchitis, emphysema,asthma or any other lung disease.
- History or presence of pulmonary tuberculosis.
- Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks prior to the screening visit.
- History or presence of significant cardiovascular, endocrinal, neurologic, immunological, psychiatric or metabolic disease.
- History of significant alcohol or drug abuse within one year prior to the screening visit.
- Regular use of alcohol within six months prior to screening visit (more than 14 alcohol units per week) [1Unit =150 ml of wine, 360 ml of beer, or 45 ml of 40% alcohol].
- Inability to abstain from alcohol for the duration of study period.
- Presence of disease markers for Hepatitis B, Hepatitis C or HIV at screening.
- Positive results for drugs of abuse (barbiturates, marijuana, opioids, benzodiazepines and methadone) in saliva before each administration.
- Positive alcohol breath test before each administration.
- Use of soft drugs (such as marijuana) within three months prior to screening or hard drugs such as crack, cocaine or heroin within one year prior to screening visit
- Intake of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers are barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; examples of inhibitors are, erythromycin, ketoconazole, indinavir, cobicistat-containing products) within one month prior to administration of the study medication. Under these circumstances, subject inclusion will be judged by the principal investigator.
- History of peptic ulcer, other gastrointestinal disorders (e.g. chronic diarrhoea, irritable bowel syndrome) or unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting) or significant hepatic, renal or other condition that is known to interfere with the absorption, distribution, metabolism or excretion of the drug.
- Use of oral or parenteral corticosteroids in the previous four 4 weeks
- Eye disorders especially Glaucoma (or a family history of glaucoma)
- Use of prescription medication (within 14 days prior to the first administration of study medication) or over-the-counter (OTC) products (including food supplements vitamins and herbal supplements) within one week (7 days) prior to the first administration of study medication, except for topical products without systematic absorption. Contraceptives are allowed.
- Vaccination for prophylaxis from seasonal flu or any other vaccination within seven days prior to administration
- History of allergy to any food, intolerance or special diet, that in the opinion of the medical sub-investigator could contraindicate the subject's participation in the study.
- A depot injection or an implant of any drug (except hormonal contraceptives) within 3 months prior to treatment administration.
- Donation of plasma (500 ml) within 7 days prior to treatment administration.
- Donation of whole blood or loss of whole blood ≥ 500 ml prior to administration of the study medication within 30 days prior to treatment administration.
- Participation in another clinical trial simultaneously.
- Subjects receiving special diet or having intolerance in any of the provided study meals or refusing to eat the study meals
- Application of tattoo or body piercing within 30 days prior to treatment administration.
- Non-tolerance to venipuncture.
- Breastfeeding women.
- Positive pregnancy test at screening
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06025214
Contact: Chrysoula Kokkali, MSc | +30 2410257310 | ckokkali@becro.gr | |
Contact: Chrysoula Doxani, Dr. | +30 2410257310 | doxani@becro.gr |
Greece | |
BECRO Clinical Facility | Recruiting |
Larissa, Thessaly, Greece, 41100 | |
Contact: Chrysoula Doxani, MD, MSc, PhD +30 2410257310 doxani@becro.gr | |
Contact: Chrysoula Kokkali, MSc +30 2410257310 ckokkali@becro.gr |
Principal Investigator: | Chrysoula Doxani, Dr. | Becro Ltd. |
Responsible Party: | Respirent Pharmaceuticals Co Ltd. |
ClinicalTrials.gov Identifier: | NCT06025214 |
Other Study ID Numbers: |
BECRO/RESP/AEROPK500 |
First Posted: | September 6, 2023 Key Record Dates |
Last Update Posted: | September 6, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
bioequivalence fluticasone propionate salmeterol xinafoate ADVAIR |
Respiratory Aspiration Respiration Disorders Respiratory Tract Diseases Pathologic Processes Fluticasone Xhance Salmeterol Xinafoate Fluticasone-Salmeterol Drug Combination Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents |
Respiratory System Agents Dermatologic Agents Anti-Allergic Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Sympathomimetics |